Protective effects of Araloside C against myocardial ischaemia/reperfusion injury: potential involvement of heat shock protein 90

Min Wanga, #, Yu Tiana, #, Yu-yang Dua, Gui-bo Suna, *, Xu-dong Xua, Hai Jiang a, b, Hui-bo Xuc, Xiang-bao Meng a, Jing-yi Zhanga, Shi-lan Dinda, Miao-di Zhanga, Ming-hua Yangd, Xiao-bo Suna, *

a Beijing Key Laboratory of Innovative Drug Discovery of Traditional Chinese Medicine (Natural Medicine) and Translational Medicine, Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
b Key Laboratory of Chinese Materia Medica (Ministry of Education), Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang, China
c Academy of Chinese Medical Sciences of Jilin Province, Changchun, Jilin, China
d Harbin University of Commerce, Harbin, Heilongjiang, China

Received: September 3, 2016; Accepted: December 28, 2016

Abstract

The present study was designed to investigate whether Araloside C, one of the major triterpenoid compounds isolated from Aralia elata known to be cardioprotective, can improve heart function following ischaemia/reperfusion (I/R) injury and elucidate its underlying mechanisms. We observed that Araloside C concentration-dependently improved cardiac function and depressed oxidative stress induced by I/R. Similar protection was confirmed in isolated cardiomyocytes characterized by maintaining Ca2+ transients and cell shortening against I/R. Moreover, the potential targets of Araloside C were predicted using the DDI-CPI server and Discovery Studio software. Molecular docking analysis revealed that Araloside C could be stably docked into the ATP/ADP-binding domain of the heat shock protein 90 (Hsp90) protein via the formation of hydrogen bonds. The binding affinity of Hsp90 to Araloside C was detected using nanopore optical interferometry and yielded KD values of 29 μM. Araloside C also up-regulated the expression levels of Hsp90 and improved cell viability in hypoxia/reoxygenation-treated H9c2 cardiomyocytes, whereas the addition of 17-AAG, a pharmacologic inhibitor of Hsp90, attenuated Araloside C-induced cardioprotective effect. These findings reveal that Araloside C can efficiently attenuate myocardial I/R injury by reducing I/R-induced oxidative stress and [Ca2+]i overload, which was possibly related to its binding to the Hsp90 protein.

Keywords: Araloside C ● ischaemia/reperfusion ● heat shock protein 90 ● biomolecular interactions

Introduction

Myocardial ischaemia/reperfusion injury (MIRI), which causes increased myocardial dysfunction and further cardiomyocyte death, is considered to be one of the leading causes of mortality and morbidity after cardiac operations and myocardial infarctions [1]. The pathogenesis of I/R injury is complicated and multi-factorial, which primarily includes excessive reactive oxygen species (ROS) production and intracellular calcium overload [2, 3]. In the past several decades, although several pharmacological and mechanical approaches (such as ischaemic pre- or post-conditioning) have been developed to limit myocardial I/R injury, this disease is still a major clinical challenge with life-threatening outcomes [4, 5]. Therefore, it is necessary to further develop novel therapeutic agents and strategies in the treatment of MIRI.

Heat shock protein (Hsp) 90, as a highly abundant and ubiquitous molecular chaperone, has been found to interact with a large number of client proteins, including members of the Src kinase family of non-receptor tyrosine kinases, Raf and other serine/threonine kinases, transcription factors such as steroid hormone receptors and p53, and eNOS [6]. In recent years, studies have shown that HSP90 may confer a cardioprotective effect against ischaemia/reperfusion injury [7, 8]. Targeted overexpression of Hsp90 in myocardium reduces infarct size and enhances the
Araloside C exerts cardioprotective effects in myocardial I/R injury and to investigate the molecular targets underlying the cardioprotective properties and underlying mechanisms of Araloside C are distinctly stimulate heart activity [21, 22]. However, the cardioprotective effects of Araloside C.

Aralia elata (Miq) Seem, a well-known adaptogenic plant, has been traditionally used as a tonic herb to increase energy and improve the body’s ability to prevent hypoxia [11, 12]. The saponins of Aralia elata (AS) are considered the main pharmacologically active ingredient extracted from A. elata [13]. Our previous studies confirmed that AS exhibits anti-myocardial ischaemic and anti-hypoxic activities [14, 15]. Moreover, A. elata Xinmaitong capsules (Clinical Trial Approval Number 2003LO1111 from China Food and Drug Administration), which we developed for the treatment of coronary heart disease, are mainly composed of AS [11]. Various oleanane-type triterpene saponins were isolated and identified from AS, which might contribute to the cardioprotective effects of AS [16–18]. For example, Elatoside C was recently reported to significantly reduce cardiac injury during I/R and alleviate hypoxia/reoxygenation (H/R)-induced cardiomyocyte apoptosis [19, 20]. Thus, it is interesting to explore the active compounds from AS with cardioprotective potentials. Araloside C (Fig. 1), one of the most abundant triterpenoid compounds isolated from A. elata, has been previously identified to distinctly stimulate heart activity [21, 22]. However, the cardioprotective properties and underlying mechanisms of Araloside C are largely unknown.

Therefore, the present study was designed to determine whether Araloside C exerts cardioprotective effects in myocardial I/R injury and to investigate the molecular targets underlying the cardioprotective effects of Araloside C.

Materials and methods

Materials

Araloside C was obtained from the Institute of Medicinal Plant Development (Beijing, China); for details, see Supplementary material. Collagenase Type II and Fura-2/AM were purchased from Life Technologies Corporation (Carlsbad, CA, USA). The kits for determining malondialdehyde (MDA) content, glutathione peroxidase (GSH-Px) activity and superoxide dismutase (SOD) activity were obtained from Jiancheng Bioengineering Institute (Nanjing, China). Cell culture products were purchased from Gibco BRL (Grand Island, NY, USA). MITT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] and 17-allylamino-17-demethoxygeldanamycin (17-AAG) were the products of Sigma Chemical Co. (St. Louis, MO, USA). The total ROS detection kit was obtained from Enzo Life Sciences (Farmingdale, NY, USA). Primary antibodies against Hsp90 and β-actin were obtained from Abcam (Cambridge, UK). Horseradish peroxidase (HRP)-conjugated secondary antibodies were secured from CW Biotech (Beijing, China). All chemical reagents were of at least analytical grade.

Animals and ethics

Male Sprague-Dawley rats (180–250 g) were purchased from Beijing Vital River Laboratory Animal Technology Co., Ltd., Beijing, China. The animals were housed under standard laboratory conditions (25 ± 1°C, 60% humidity, with a 12-hrs photoperiod) and provided free access to sterile food and water. All of the procedures were approved by the Laboratory Animal Ethics Committee of the Institute of Medicinal Plant Development, Peking Union Medical College, and conformed to the Guide for the Care and Use of Laboratory Animals (NIH publication No. 86-23, revised 1996).

Isolated rat heart Langendorff perfusion

As described in our previous study [20], male Sprague–Dawley rats were anesthetized with sodium pentobarbital (45 mg/kg i.p.) and heparinized. Next, the heart was rapidly excised and cannulated on a Langendorff perfusion system through the aorta and perfused at a constant pressure of 80 mmHg with Krebs–Henseleit (KH) buffer (37°C, pH 7.4), which was constantly gassed with 95% O2 and 5% CO2. The left ventricular pressure and heart rate (HR) were measured via a pressure transducer (AD Instruments, Sydney, NSW, Australia) that was connected to a water-filled wrap balloon inserted into the left ventricle, achieving a left ventricular end-diastolic pressure (LVEDP) between 2 and 8 mmHg. The isolated heart was surrounded by a homoepothermic glass cover (37°C) to maintain temperature. All of the data were recorded using PowerLab and analysed using Chart V 7.3.3 (AD Instruments).

Experimental protocols in isolated hearts

All of the hearts were stabilized with KH buffer for a period of 30 min before the application of the experimental protocols described in this study. To determine the concentration–response relationship of Araloside C on the recovery of post-ischaemic myocardial function, the
 hearts were randomly divided into the following experimental groups (n = 15 hearts/group): (i) control, the isolated hearts were perfused for 90 min. with oxygenated KHB; (ii) I/R, the isolated hearts were perfused with KHB for 15 min. and then subjected to 45 min. of no-flow global ischaemia and 30 min. of reperfusion; and (iii) Araloside C + I/R, the isolated hearts were perfused with KHB containing Araloside C at concentrations of 0.5, 1 and 2.5 μM for 15 min. prior to I/R.

**Determination of oxidative stress-related indicators in isolated hearts**

The left ventricle was harvested, and myocardial homogenates were prepared for the detection of MDA, GSH-Px and SOD by the corresponding kits (Nanjing Jiancheng Bioengineering Institute, Nanjing, China) as per the manufacturer’s instructions. The activities of NADPH oxidase were investigated by NADPH Oxidase Activity Detection kit (Genmed Scientifics INC., Shanghai, China). ROS levels were detected by the Rat ROS ELISA kit (RapidBio Lab, Calabasas, CA, USA).

**Isolation of adult rat ventricular myocytes**

Individual rat left ventricular myocytes were isolated using an enzymatic method as previously reported [11]. Only isolated rod-shaped myocytes accounting for >85% at the beginning of each experiment were considered satisfactory.

**Simultaneous measurement of Ca2+ transients and sarcomere shortening**

Ca2+ transients and sarcomere shortening were detected simultaneously using a video-based sarcomere length and Ca2+ acquisition module system (IonOptix Corporation, Milton, MA, USA), as previously described [11]. Cardiomyocytes were incubated with Fura-2 AM (2 μM for 20 min. at 37°C; Invitrogen, Carlsbad, CA, USA). The loaded cells were electrically stimulated at 0.5 Hz. The ratio of fluorescence emitted at 340 and 380 nm was recorded as an indicator of [Ca2+]i. The data were recorded and analysed with IonWizard software (version 6.2.0.59, IonOptix LLC, Milton, MA, USA).

**Experimental protocols in isolated cardiomyocytes**

A cellular model of simulated I/R was used as previously described [20]. Briefly, control recordings were made for 15 min. in normal Tyrode’s solution at 37°C, pH 7.4. Subsequently, the solution was switched to an ischaemic solution (in mM: 123 NaCl, 6 NaHCO3, 0.9 NaH2PO4, 8 KCl, 0.5 MgSO4, 20 Na lactate and 1.8 CaCl2; pH 6.8 and equilibrated with 90% N2–10% CO2) for 20 min. followed by a 30-min. repertusion with normal Tyrode’s solution. The effects of Araloside C on Ca2+ transients and sarcomere shortening during I/R were examined by perfusing cells with Araloside C (2–8 μM) for 5 min. prior to ischaemia. Time controls were exposed to normal Tyrode’s solution for 65 min. without ischaemia.

**Prediction of the targets of Araloside C by bioinformatic approach**

**Targets predicted by the CPI**

The interaction information of Araloside C was predicted using the DDI-CPI tool, a web-based server that can predict drug–drug interactions via the chemical–protein interactome. The molecular file of Araloside C was downloaded and pre-treated following the web instructions. Next, the file was submitted to the DDI-CPI servers. Parameters were set to default values.

**Targets predicted by Discovery Studio 4.5**

The molecular targets of Araloside C were predicted using Discovery Studio 4.5 (BIOVIA Software Inc., San Diego, CA, USA), a software suite for performing computational analysis of data relevant to Life Sciences research. To determine the proper target of Araloside C, we employed the Ligand Profiler protocol which maps a set of pharmacophores, including Pharma DB by default. The ligand of Araloside C was prepared by the Specifying Ligands parameter protocol. After inputting all parameters, the job was run and the results were monitored from the Jobs Explorer.

**Molecular docking**

To explore the potential interacting mode of Araloside C with the Hsp90 protein (PDB code: 1AMW), a molecular modelling study was performed using the docking program named Lib Dock, a software package in Discovery Studio 4.5. To eliminate any bond length and bond angle biases, the ligand (Araloside C) was subjected to a full minimization prior to docking. The binding affinities (LibDockScore) in Discovery Studio 4.5 were used to evaluate the interactions between Hsp90 and Araloside C.

**Nanopore optical interferometry**

Label-free molecule/protein interaction detection and kinetic constant measurement were studied using the SKi Pro System (Silicon Kinetics, San Diego, CA, USA) [23]. Nanoporous carboxy chips were activated using sulpho-NHS/EDAC chemistry in a buffer consisting of 0.1 M MES pH 6 and 0.15 M NaCl. The chips were subsequently immobilized with the recombinant human Hsp90 protein at a concentration of 0.5 mg/ml in 20 mM sodium acetate, pH 4.5 and then blocked with 1 M ethanolamine, pH 8.0. Araloside C was prepared as a 10 mM solution in running buffer before the experiment and diluted two-fold by running buffer into 80, 40, 20, 10 and 0 μM before injection. The optical interference pattern was recorded as a change in optical path difference in units of nm. Data were analysed with SKi Report software.

**Cell culture and Hypoxia/Reoxygenation**

The H9c2 cardiomyocyte line was obtained from the Chinese Academy of Sciences Cell Bank (Shanghai, China) and cultured as previously described [24]. Briefly, H9c2 cells were cultured in high-glucose DMEM supplemented with 10% (v/v) foetal bovine serum, 1% penicillin/
streptomycin (v/v) and 2 mM l-glutamine. The cells were maintained at 37°C with 100% relative humidity in a CO₂ incubator containing 5% CO₂ at 37°C.

The hypoxia/reoxygenation (H/R) procedures were modified from a previous study [19, 25]. For all experiments, cells were plated at an appropriate density according to the experimental design and were grown for 24 hrs to reach 70-80% confluence before experimentation.

**Experimental protocols in H9c2 cardiomyocytes**

The cultured H9c2 cardiomyocytes were randomly divided into different groups. In the control group, the H9c2 cardiomyocytes were incubated under normoxic conditions for equivalent durations with high-glucose DMEM. The H/R group was conducted as described in the preceding section. In the Araloside C-treated group (H/R + A-C), the H9c2 cardiomyocytes were pre-treated with Araloside C for 12 hrs before subjected to H/R. Inhibitor-treated groups were processed the same as the H/R + A-C group, but the cells were incubated with 2 μM 17-AAG for 1 hr before they were treated with Araloside C.

**Cell viability analysis**

Cell viability was determined by the 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium (MTT) assay as previously described [19]. Briefly, H9c2 cells were plated on 96-well plates at a density of 1 x 104 cells/well. After designated treatment, 20 μl MTT (5 mg/ml) was added to each well and incubated for 4 hrs. The medium was then removed, and the formazan crystals were dissolved with dimethyl sulphoxide (DMSO). Absorbance was read at 570 nm on a microplate reader (TECAN Infinite M1000, Austria).

**Measurement of ROS production in cardiomyocytes**

The cellular ROS levels were determined according to the manufacturer’s protocol using total ROS detection kits (Enzo Life Sciences Inc., Farmingdale, NY, USA) as previously described [26]. Briefly, following treatment, the cells were incubated with 100 μl of 5-(and-6)-carboxy-2', 7'-dichlorodihydrofluorescein diacetate (carboxy-H2DCFDA) (25 μM final concentration) in darkness at 37°C for 30 min. Cellular DCF fluorescence intensity was determined through microplate reader with excitation wavelength of 495 nm and emission wavelength of 529 nm. The ROS level was expressed as a percentage of the control.

**Western blot**

Cell lysate preparation and Western blot analysis were performed as previously described [19]. The primary antibodies were against Hsp90 and β-actin (Abcam, Cambridge, UK). Specific bands were visualized after incubation with horseradish peroxidase-conjugated secondary antibodies by enhanced chemiluminescence using a Bio-Rad imaging system (Bio-Rad, Hercules, CA, USA).

**Statistical analyses**

The results are expressed as the means ± standard deviation. Comparisons between >2 groups or multiple groups over time were performed using simple or repeated-measures ANOVA (Prism 5.00 software, GraphPad Software Inc, La Jolla, CA, USA) as appropriate. A Newman–Keuls post hoc test was used, except in the analysis of Langendorff data, where Bonferroni’s analysis was used. Statistical significance was set at P < 0.05. All data are the result of at least three independent experiments.

**Results**

**Araloside C improved cardiac function of I/R hearts**

To characterize the cardioprotective effects of Araloside C against I/R injury, we perfused isolated rat hearts with Araloside C at concentrations from 0.5 to 2.5 μM for 15 min. prior to ischaemia. Compared with the I/R group, Araloside C (0.5–2.5 μM) concentration-dependently improved the functional recovery of the I/R hearts, including increase in the recovery of LVDP, ±dP/dtmax and heart rate throughout the reperfusion period, although the baseline mechanical parameters with Araloside C were not significantly different compared with those of the control condition (Fig. 2A–D). In the additional groups, we found that Araloside C treatment alone did not have a significant effect on the mechanical parameters after 90 min. of perfusion compared with those of the control group (data not shown).

**Araloside C reduced I/R-induced myocardial oxidative stress**

Malondialdehyde levels were used as surrogate assays for membrane lipid oxidation, which is one of the primary events in oxidative damage [27]. We found that the MDA levels, ROS levels and NADPH oxidase were significantly lower in the Araloside C-treated (2.5 μM) group compared with those of the I/R group. Consistently, the activities of the major cellular antioxidants GSH-Px and SOD in the rat myocardium were decreased in the I/R group and significantly elevated by treatment with Araloside C (Fig. 3).

**Araloside C improved the impairment of cardiomyocyte contractile capacity and intracellular Ca²⁺ homeostasis induced by I/R**

Our further assessment of the cardiomyocyte mechanics revealed that Araloside C could improve post-ischaemic cell shortening and Ca²⁺ transients from 2 to 8 μM. I/R markedly depressed the peak shortening (PS) amplitude and the maximal velocity of shortening/re-lengthening (±dL/dt), accompanied by a prolonged duration of re-lengthening (TR90) and duration of shortening (TPS). However, all of these effects were significantly attenuated by pre-treatment with Araloside C (Fig. 4).
Fig. 3 Effects of Araloside C on oxidative damage in I/R-injured hearts. SOD: superoxide dismutase; GSH-PX: glutathione peroxidase. MDA: malondialdehyde; ROS: reactive oxygen species; NADPH oxidase: nicotinamide adenine dinucleotide phosphate oxidase; A-C: Araloside C. n > 10 in each group, ##P < 0.01 versus baseline control; *P < 0.05 versus I/R control; ***P < 0.01 versus I/R control.

© 2017 The Authors.
Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
I/R induced a significant increase in resting levels of Ca\textsuperscript{2+} transients that represent the diastolic cytosolic Ca\textsuperscript{2+} content, but this increase was markedly restored by Araloside C (Fig. 5A). The amplitude of the Ca\textsuperscript{2+} transients and the maximum upstroke velocity (\(V_{\text{max}}\)) of Ca\textsuperscript{2+} transients were decreased after I/R, while Araloside C significantly attenuated those suppressions (Fig. 5B and C). The decay of [Ca\textsuperscript{2+}]i, representing the speed of Ca\textsuperscript{2+} removal from the cytoplasm, mainly via sarco/endoplasmic reticulum Ca\textsuperscript{2+}-ATPase (SERCA), was significantly prolonged during I/R. Araloside C reduced the decay of [Ca\textsuperscript{2+}]i close to the control level, suggesting an increase in SERCA activity (Fig. 5D).

**Target prediction**

The molecular targets of Araloside C were predicted using the web-based DDI-CPI tool and Discovery Studio software, respectively. More than seventy potential targets were identified and annotated to have significant relationships with the pharmacologic effects of Araloside C (Table 1). Among these targets, we focused on the heat shock protein 90 (Hsp90), which is a critical target in the protection of the myocardium from I/R injury.

**Docking analysis of the interaction between Araloside C and Hsp90**

Following prediction of the molecular target, we examined the possible interaction between Araloside C and the Hsp90 protein using Discovery Studio 4.5. Molecular modelling of Araloside C revealed that it was bound deeply into the binding cavity of Hsp90 and showed important conventional hydrogen bond interaction with the amino acid residues Asn 37, Asn92 and Phe124 (Fig. 6A). As seen in Figure 6B, Gly 121 and Glu 88 are responsible for binding the
glycosyl moiety in the extracted Araloside C with carbon–hydrogen bond interactions. Additionally, it seemed that the presence of triterpenoid aglycone backbone on Araloside C led to the formation of weak alkyl interaction with amino acid residues Lys 44, Ala 41 and Met 84, which are important to the binding site. The LibDockScore (133.521) was obtained based on the virtual calculation of the interaction of Araloside C with the targeted Hsp90 protein.

Araloside C binds to Hsp90 in a dose-dependent manner

To further characterize the interaction between Araloside C and Hsp90, we determined the binding affinity kinetic constants using SKi Pro nanopore optical interferometry. Hsp90 was immobilized to the nanoporous silicon chip, and the Araloside C was provided at varying concentrations. As shown in Figure 7, Araloside C bound to Hsp90 in a dose-dependent manner. The resultant KD constant of Araloside C binding to Hsp90 was 29 µM, indicating the likelihood of direct binding of Araloside C to Hsp90.

Hsp90 contributes to the cytoprotection of Araloside C against H/R injury in H9c2 cardiomyocytes

Studies have shown that overexpression of HSP90 can protect cardiac myocytes against ischaemia/reperfusion injury [8]. In Araloside C-treated H9c2 cells, Hsp90 expression was increased in a time-dependent manner (Fig. S2). To further investigate the potential role of Hsp90 in Araloside C-induced cardioprotection, we then detected the effects of Araloside C on Hsp90 expression levels in H/R-treated cardiomyocytes. Figure 8A shows that Araloside C treatment significantly inhibited the down-regulation of the H/R-induced Hsp90 (both Hsp90α and Hsp90β) expression. To determine whether such elevated expression of Hsp90 can contribute to Araloside C-mediated
protection against H/R-induced cytotoxicity, a selective inhibitor of Hsp90, 17-AAG, was utilized. Araloside C considerably attenuated H/R-induced cytotoxicity, evidenced by enhanced phosphorylation of pro-survival protein Akt, improved cell viability and decreased ROS level. However, this cytoprotection of Araloside C treatment was reduced by 17-AAG pre-treatment (Fig. 8B and C), which suggested that Hsp90 is involved in the protective effect of Araloside C against H/R injury in H9c2 cells.

Discussion

In the present study, we not only determined the concentration-dependent cardioprotection of Araloside C, but also identified the possible molecular target of Araloside C. We observed the following: (i) Araloside C ameliorates myocardial dysfunction and depresses oxidative stress in I/R hearts; (ii) Araloside C improves cardiomyocyte contraction and Ca^{2+} transients during I/R; and (iii) the cardioprotective effect of Araloside C is dependent on its binding to the Hsp90 protein. These findings provide novel evidence and insights related to the role of Araloside C against myocardial I/R injury.

Numerous reports indicate that myocardial ischaemia/reperfusion would cause a sharp decline in cardiac function, leading to a marked decrease in LVSP, heart rate and ventricular contractility [20, 28]. The present study has provided evidence that Araloside C pre-treatment concentration-dependently promotes the recovery of I/R-induced myocardial dysfunction in rats. More specifically, at the end (30 min.) of reperfusion, LVSP was 86.11 ± 8.82% of baseline levels in the Araloside C+I/R treatment group, while Elatoside C, another major triterpenoid saponin isolated from A. elata, was 75.66 ± 10.2% of baseline levels at the 30 min. of reperfusion in our previous report [20]. It seems that the effect of Araloside C is a little stronger than that of Elatoside C on cardiac function of the I/R hearts. However, there is no statistically significant difference between Araloside C pre-treatment group and Elatoside C group. After initial investigation of the effect of Araloside C on the whole heart, we then further observed the effect on the cellular level. We demonstrated that Araloside C significantly improves contractile function in I/R cardiomyocytes. Our observations indicate that Araloside C has a beneficial effect on cardiac performance during I/R.

Excessive ROS production and calcium overload are the two proposed mechanisms of cardiac dysfunction in I/R injury [2, 29]. ROS overproduction causes damage to the cell membranes in rat hearts,
subsequently causes cell membrane lipid peroxidation and results in myocardial structural failure [30]. In this study, we investigated the effects of Araloside C on oxidative stress in I/R hearts. Our results clearly showed that SOD activity and GSH-Px were significantly elevated as a result of Araloside C pre-treatment, whereas these effects were accompanied by significantly decreased levels of MDA and ROS, indicating that the cardioprotective effects of Araloside C may possibly be ascribed to its direct antioxidant property. Alternatively, reperfusion can lead to a dramatic rise of \([\text{Ca}^{2+}]_i\) due to abnormal Ca\(^{2+}\) handling [29, 31]. The present data show that Araloside C significantly improves cell contraction and Ca\(^{2+}\) transients in isolated cardiomyocytes during I/R. The reduced activity of ryanodine receptors (RyRs) at the end of reperfusion would be detrimental to the contractility due to the depression of Ca\(^{2+}\) release from the sarcoplasmic reticulum (SR) [32]. Here, we show that the amplitude of Ca\(^{2+}\) transients and the speed of Ca\(^{2+}\) release via RyRs were significantly faster in the Araloside C group, suggesting that Araloside C improved the activity of RyRs. The decay of [Ca\(^{2+}\)_i] represents the speed of Ca\(^{2+}\) uptake mainly via SERCA [33]. The depressed decay rate of [Ca\(^{2+}\)_i] transience stimulated by Araloside C can be interpreted at least in part to the preserved protein content and activity of the SERCA during I/R. Thus, we speculate that Araloside C may suppress I/R-induced Ca\(^{2+}\) overload by reserving the protein content and function of RyRs and SERCA, thereby maintaining relatively normal Ca\(^{2+}\) homeostasis during I/R, leading to improvement in contractility. Taken together, the beneficial effects of Araloside C on myocardial I/R injury seem to be largely due to the attenuation of oxidative stress and the maintenance of [Ca\(^{2+}\)_i] homeostasis.

Bioinformatic approaches have become a powerful tool for interpretation and prediction of the potential biological activities of drugs and their targets [34, 35]. We therefore used a DDI-CPI tool and Discovery Studio software to predict the potential targets of Araloside C. Our findings show that Araloside C can modulate a number of functional protein targets. Among the number of targets identified by screening, Hsp90, one of the most abundant and conserved molecular chaperones, has been shown to protect the myocardium against I/R injury [8]. Hsp90 is essential for the integrity and function of numerous signal transduction molecules and is identified directly as the effector allowing activation of the pro-survival PI3K/Akt pathway [36, 37]. Previous studies have shown that Hsp90 plays a vital role in ischaemic pre-conditioning and post-conditioning [7, 38]. Targeted overexpression of Hsp90 in myocardium reduces infarct size and myocardial dysfunction [9]. However, the Hsp90 inhibitor increases cardiomyocyte apoptosis through reducing pro-survival Akt signalling and enhancing the activity of pro-apoptotic BAD [39]. In isolated hearts, Hsp90 also has been shown to facilitate protein kinase C\(\varepsilon\) targeting to mitochondria, ultimately attenuating I/R-induced cardiomyocyte apoptosis and necrosis [40]. Notably, the recent study shows that Hsp90 appears to modulate the inhibitory function of HAX-1 on calcium cycling and supports certain of its cardioprotective effects at the ER/SR [41]. Moreover, the HAX-1/Hsp90 complex may also inhibit activation of the mPTP via regulation of cyclophilin-D (Cyp-D).

Fig. 8 Effects of Hsp90 on the protection of Araloside C against H/R-induced cell injury. (A) Effects of Araloside C on Hsp90 expression and Akt phosphorylation levels in H/R-treated cardiomyocytes. Cell lysates were harvested, and Western blot analysis was performed. β-actin expression was examined as the protein loading control. (B) Effects of Araloside C and the Hsp90 inhibitor 17-AAG on cell viability in H/R-treated cardiomyocytes. Cardiomyocyte viability was assessed using the MTT assay. (C) Effects of Araloside C and 17-AAG on reactive oxygen species (ROS) levels in H/R-treated cardiomyocytes. The intracellular ROS levels were measured with a fluorometric assay. H/R, Hypoxia/reoxygenation; A-C, Araloside C. The data are expressed as means ± S.D. from three independent experiments. *P < 0.05 versus control; **P < 0.01 versus control; *P < 0.05 versus H/R-treated cells; **P < 0.01 versus H/R-treated cells; $P < 0.05 versus H/R + A-C-treated cells; $$$P < 0.01 versus H/R + A-C-treated cells.
levels and promote cardiomyocyte survival upon oxidative stress and calcium overload in ischaemia/reperfusion injury [42].

Because Hsp90 played a crucial role to modulate cardioprotection against myocardial I/R injury and was predicted to be a potential target of Araloside C, we selected it for our subsequent confirmative assays. Molecular docking is a commonly and frequently applied technique to predict the specific positioning of a ligand in the active site of a protein [43, 44]. The molecular docking study using the Discovery Studio program showed that Araloside C was indeed docked closely in the active site of Hsp90. Moreover, we have characterized the kinetic association constants between Araloside C and Hsp90 using nanopore optical interferometry. Our results demonstrated that Araloside C was able to bind to the Hsp90 protein in vitro in a dose-dependent manner with the KD 29 μM. Because our studies indicated an interaction between Araloside C and Hsp90, we also investigated the effects of Hsp90 on the protection of Araloside C against hypoxia/reoxygenation (H/R) injury for H9c2 cardiomyocytes. These experiments revealed that treatment with Araloside C significantly attenuated the cytotoxicity and the down-regulation of Hsp90 expression induced by H/R, which was consistent with the findings in IR-injured isolated hearts (Fig. S3). Notably, inhibition of Hsp90 via the Hsp90 inhibitor 17-AAG significantly blocked the Araloside C-induced cardioprotective effect against H/R injury, as demonstrated by inhibited Akt activation, decreased cell viability and increased ROS levels. Cumulatively, the computational and experimental data presented here highly support the speculation that Araloside C may help attenuate myocardial I/R injury and was predicted to be a potential target of miR-1 in cardiac ischemia/reperfusion injury. These observations provide evidence supporting Araloside C as a promising therapeutic candidate for myocardial I/R injury in cardiac surgery and ischaemic heart disease.

Acknowledgements

This study was supported by the National Natural Sciences Foundation of China (Grant Nos. 81473380, 81603333 and 81302656), the Natural Sciences Foundation of Beijing (Grant Nos. 7142108, 7152102 and 7144225), the Special Research Project for TCM (Grant No. 201507004), CAMS Innovation Fund for Medical Sciences (CIFMS) (Grant No. 2016-i2M-1-012) and the Program for Innovative Research Team in IMPLAD (Grant No. IT1301).

Conflicts of interest

The authors confirm that there are no conflicts of interest.

Supporting information

Additional Supporting Information may be found online in the supporting information tab for this article:

Appendix S1 Methods.

Figure S1 HPLC (UV) chromatogram of Araloside C.

Figure S2 Effects of Araloside C on Hsp90 expression levels in H9c2 cardiomyocytes.

Figure S3 Effects of Araloside C on Hsp90 expression levels in IR-injured isolated rat hearts.

References

1. Sharma V, Bell RM, Yellon DM. Targeting reperfusion injury in acute myocardial infarction: a review of reperfusion injury pharmacotherapy. Expert Opin Pharmacother. 2012; 13: 1155–73.
2. Kalogeris T, Baines CP, Krenz M, et al. Cell biology of ischemia/reperfusion injury. Int Rev Cell Mol Biol. 2012; 298: 229–317.
3. Davidson SM, Yellon DM, Murphy MP, et al. Slow calcium waves and redox changes precede mitochondrial permeability transition pore opening in the intact heart during hypoxia and reoxygenation. Cardiovasc Res. 2012; 93: 445–53.
4. Gerczuk PZ, Klomer RA. An update on cardioprotection: a review of the latest adjunctive therapies to limit myocardial infarction size in clinical trials. J Am Coll Cardiol. 2012; 59: 969–78.
5. Miura T, Miki T. Limitation of myocardial infarct size in the clinical setting: current status and challenges in translating animal experiments into clinical therapy. Basic Res Cardiol. 2008; 103: 501–13.
6. Picard D. Heat-shock protein 90, a chaperone for folding and regulation. Cell Mol Life Sci. 2002; 59: 1640–8.
7. Zhong QQ, Tu RH, Zeng ZY, et al. Novel functional role of heat shock protein 90 in protein kinase C-mediated ischemic post-conditioning. J Surg Res. 2014; 189: 198–206.
8. Zhu WS, Guo W, Zhu JN, et al. Hsp90a1: a novel target gene of miR-1 in cardiac ischemia/reperfusion injury. Sci Rep. 2016; 6: 24498.
9. Kupatt C, Dessy C, Hinkel R, et al. Heat shock protein 90 transfection reduces ischemia-reperfusion-induced myocardial dysfunction via reciprocal endothelial NO synthase serine 1177 phosphorylation and threonine 495 dephosphorylation. Atheroscler Thromb Vasc Biol. 2004; 24: 1435–41.
10. Griffin TM, Valdez TV, Mestri R, Radiciol activates heat shock protein expression and cardioprotection in neonatal rat cardiomyocytes. Am J Physiol Heart Circ Physiol. 2004; 287: 1081–8.
11. Wang M, Xu X, Xu H, et al. Effect of the total saponins of Aralia elata (Miq) Seem on
cardiac contractile function and intracellular calcium cycling regulation. *J Ethnopharmacol.* 2014; 155: 240–7.

12. Baranov AI. Medicinal uses of ginseng and related plants in the Soviet Union: recent trends in the Soviet literature. *J Ethnopharmacol.* 1982; 6: 339–53.

13. Xu XD, Yang JS, Zhu ZY. Advances in the studies of saponins from *Aralia*. *Yao Xue Bao*. 1997; 32: 711–20.

14. Sun G, Xu H, Wen F, et al. Protective effects of araliasides on cultured myocardial cells subjected to anoxia/reoxygenation injury. *Chin Pharmaco Bull*. 2006; 22: 1092–5.

15. Deng HW, Li YJ, Shen N, et al. Protective effect of araloides of *Aralia elata* on experimental myocardial ischemia of rats. *Chin J Pharmacol*. 1988; 2: 20–3.

16. Nhoim NX, Lim HY, Kiern P, et al. Oleane-type triterpene saponins from the bark of *Aralia elata* and their NF-kappaB inhibition and PPAR activation signal pathway. *Bioorg Med Chem Lett.* 2011; 21: 6143–7.

17. Wang Z, Song S, Lu H, et al. Effect of three triterpenoid compounds isolated from root bark of *Aralia elata* on stimulus-induced superoxide generation and tyrosyl phosphorolyation and translocation of p47(phox) and p67(phox) to cell membrane in human neutrophil. *Clin Chim Acta*. 2003; 336: 65–72.

18. Lee JH, Ha YW, Jeong CS, et al. Isolation and tandem mass fragmentations of an anti-inflammatory compound from *Aralia elata*. *Arch Pharm Res*. 2009; 32: 381–40.

19. Wang M, Meng XB, Yu YL, et al. Elatoside C protects against hypoxia/reoxygenation-induced apoptosis in H9c2 cardiomyocytes through the reduction of endoplasmic reticulum stress partially depending on STAT3 activation. *Apoptosis*. 2014; 19: 1727–35.

20. Wang M, Sun GB, Zhang JY, et al. Elatoside C protects the heart from ischaemia/reperfusion injury through the modulation of oxidative stress and intracellular Ca(2+) (+) homeostasis. *Int J Cardiol*. 2015; 185: 167–76.

21. Zhang JX, Tian Y, Sun GB, et al. Research progress in chemical constituents of saponins from *Aralia elata* and their pharmacological activities. *Chinese Traditional and Herbal Drugs*. 2013; 44: 770–9.

22. Sokolov S. The influence of saponins of Manchurian aralia on the electric activity of the brain. *Biull Eksp Biol Med*. 1965; 60: 73–7.

23. Sperandio S, Tardito S, Surzycki A, et al. TOE1 interacts with p53 to modulate its transactivation potential. *FEBS Lett*. 2009; 583: 2165–70.

24. Sun X, Sun GB, Wang M, et al. Protective effects of cynarosides against H(2)O(2)-induced apoptosis in H9c2 cardiomyoblasts. *J Cell Biochem*. 2011; 112: 2019–29.

25. Sun J, Sun G, Meng X, et al. Ginsenoside RK3 prevents hypoxia-reoxygenation induced apoptosis in H9c2 cardiomyocytes via AKT and MAPK pathway. *Evid Based Complement Alternat Med*. 2013; 2013: 690190: 27.

26. Wang M, Sun GB, Sun X, et al. Cardioprotective effect of salvianolic acid B against arsenic trioxide-induced injury in cardiac H9c2 cells via the PI3K/Akt signal pathway. *Toxicol Lett*. 2013; 216: 100–7.

27. Rodrigo R, Libuys M, Feliu F, et al. Oxidative stress-related biomarkers in essential hypertension and ischemia-reperfusion myocardial damage. *Dis Markers*. 2013; 35: 773–90.

28. Libby P, Theroux P. Pathophysiology of coronary artery disease. *Circulation*. 2005; 111: 3481–8.

29. Piper HM, Meuter K, Schafer C. Cellular mechanisms of ischemia-reperfusion injury. *Ann Thorac Surg*. 2003; 75: S644–8.

30. Wang C, Liu N, Luan R, et al. Apelin protects sarcolemmal reticulum function and cardiac performance in ischaemia-reperfusion injury by attenuating oxidation of sarcoplasmic reticulum Ca2+ -ATPase and ryarodine receptor. *Cardiovasc Res*. 2013; 100: 114–24.

31. Temsah RM, Netticadan T, Chapman D, et al. Alterations in sarcoplasmic reticulum function and gene expression in ischemia-reperfused rat heart. *Am J Physiol*. 1999; 277: H584–94.

32. Chen L, Lu XY, Li J, et al. Intermittent hypoxia protects cardiomyocytes against ischemia-reperfusion injury-induced alterations in Ca2+ -homeostasis and contraction via the sarcoplasmic reticulum and Na+/Ca2+ exchange mechanisms. *Am J Physiol Cell Physiol*. 2006; 290: C1221–9.

33. Wang C, Du JF, Wu F, et al. Apelin decreases the SR Ca2+ content but enhances the amplitude of [Ca2+ ]t transients and contractions during twitches in isolated rat cardiac myocytes. *Am J Physiol Heart Circ Physiol*. 2008; 294: H2540–6.

34. Lomenick B, Olsen RW, Huang J. Identification of direct protein targets of small molecules. *ACS Chem Biol*. 2011; 6: 34–46.

35. Rollinger JN, Schuster D, Danzl B, et al. In silico target fishing for rationalized ligand discovery exemplified on constituents of Ruta graveolens. *Planta Med.* 2009; 75: 195–204.

36. Barksdale KA, Bijur GN. The basal flux of Akt in the mitochondria is mediated by heat shock protein 90. *J Neurochem*. 2009; 108: 1289–90.

37. Small BA, Lu Y, Hsu AK, et al. Morphine reduces myocardial infarct size via heat shock protein 90 in rodents. *Biomed Res Int*. 2015; 2015: 129612.

38. Amour J, Brzezinska AK, Weihrauch D, et al. Role of heat shock protein 90 and endothelial nitric oxide synthase during early anesthetic and ischemic preconditioning. *Anesthesiology*. 2009; 110: 317–25.

39. Wang W, Peng Y, Wang Y, et al. Anti-apoptotic effect of heat shock protein 90 on hypoxia-mediated cardiomyocyte damage is mediated via the phosphatidylinositol 3-kinase/AKT pathway. *Clin Exp Pharmacol Physiol*. 2009; 36: 899–903.

40. Budas GR, Churchill EH, Disatnik MH, et al. Mitochondrial import of PKC epsilon is mediated by HSP90; a role in cardioprotection from ischaemia and reperfusion injury. *Cardiovasc Res*. 2010; 88: 83–92.

41. Lam CK, Zhao W, Cai W, et al. Novel role of HAX-1 in ischemic injury protection involvement of heat shock protein 90. *Circ Res*. 2013; 112: 79–89.

42. Lam CK, Zhao W, Liu GS, et al. HAX-1 regulates cyclophilin-D levels and mitochondria permeability transition pore in the heart. *Proc Natl Acad Sci U S A*. 2015; 112: E6466–75.

43. Ban JO, Kim DH, Lee HP, et al. Anti-arthritis effects of (E)-2,4-bis(p-hydroxyphenyl)-2-butenal are mediated by inhibition of the STAT3 pathway. *Br J Pharmacol*. 2014; 171: 2900–12.

44. Foglieni C, Pagano K, Lessi M, et al. Integrating computational and chemical biology tools in the discovery of antiangiogenic small molecule ligands of FGFr2 derived from endogenous inhibitors. *Sci Rep*. 2016; 6: 23432.